Sebaceous cyst

Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago   

Retrieved on: 
Wednesday, October 12, 2022
Vestibular adenitis, LinkedIn, Innovation, Lipoma, Decompression, Ultrasound, Injury, Pelvis, Securities Act of 1933, Spine, Leiomyoma, NEXUS, Ovary, Inclusion, Failure, Surgeon, Cardiothoracic surgery, Evidence-based medicine, Twitter, Access, North American Spine Society, Company, Gastrointestinal tract, Orthopedic surgery, GLOBE, Uterine fibroid, Projection, Government, Growth, Review, Uterus, Research, Security (finance), NASS, Neurosurgery, Plastic and Reconstructive Surgery, Securities Exchange Act of 1934, MIS, U.S. Securities and Exchange Commission, General surgery, Sebaceous cyst, Terminology, Risk, Physician, Cedars-Sinai Medical Center, SEC, Patient, Nasdaq, Malignancy, Sex, Acquisition, Extremities, Forward-looking statement, COVID-19, Cardiac fibroma, Sebaceous gland, Bookbinding, Medical imaging, Gynaecology, MD

The BoneScalpel Access handpiece 20 mm blade and Micro Hook Shaver will be available throughout the U.S. on October 17.

Key Points: 
  • The BoneScalpel Access handpiece 20 mm blade and Micro Hook Shaver will be available throughout the U.S. on October 17.
  • The BoneScalpel Access handpiece allows surgeons to leverage the many advantages of ultrasonic bone cutting in minimally invasive spinal procedures.
  • Combined with OSTEOAMP Flowable, Bioventus now has a full portfolio for MIS spine procedures, the fastest growing segment of spine surgery.
  • The Bioventus surgical solutions portfolio brings together innovative products that add value for surgical applications in decompression and fusion.

Bioventus Receives US FDA Clearance for BoneScalpel® Access™

Retrieved on: 
Monday, December 20, 2021
Securities Act of 1933, Review, General surgery, Ovary, Senior, Forward-looking statement, LinkedIn, The Chartered Institute of Ergonomics and Human Factors, FDA, Projection, Physician, Growth, U.S. Securities and Exchange Commission, Sebaceous gland, Securities Exchange Act of 1934, Security (finance), Evidence-based medicine, Malignancy, Risk, GLOBE, Quality, Lipoma, Uterine fibroid, US Foods, Nasdaq, COVID-19, Gastrointestinal tract, Vestibular adenitis, SEC, Inclusion, Research, Neurosurgery, Terminology, Surgeon, Twitter, NEXUS, Failure, Food, Plastic and Reconstructive Surgery, Government, Company, Uterus, Cardiac fibroma, Orthopedic surgery, Patient, Sex, Cardiothoracic surgery, Innovation, Sebaceous cyst, Leiomyoma, Medical imaging, Dentistry, Gynaecology

DURHAM, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Companys neXus BoneScalpel Access handpiece.

Key Points: 
  • DURHAM, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Companys neXus BoneScalpel Access handpiece.
  • The BoneScalpel Access handpiece provides surgeons with a new option for confined spaces during minimally invasive surgery, enabling safe and powerful bone removal with maximum visualization.
  • Bioventus plans to launch BoneScalpel Access in 2022.
  • Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.